The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Multiple Sclerosis: Current Knowledge and Future Outlook
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal loss. The etiology of MS is unknown; however, environmental and genetic factors play a key role in the development of MS. Diagnostic criteria have been adapted to facilitate earlier diagnosis with increased sensitivity and specificity. Our understanding of the pathophysiology of MS has deepened considerably in recent years, resulting in different therapies to modify the disease course. Furthermore, several drugs have lately shown efficacy in phase III studies and their approval is expected in the near future. As treatment options expand, a future challenge will be to find the optimal treatment for the individual patient. Summary: This mini-review gives an overview of the current knowledge of MS with emphasis on the latest diagnostic criteria and both current and upcoming treatment options. Key Messages: Treatment of MS changes rapidly as the knowledge and therapeutic options in MS expand. Clinical Impact: Diagnosis of MS is based on McDonald criteria. MS therapy can be divided into relapse, disease-modifying and symptomatic treatment. Relapses are commonly treated with intravenous methylprednisolone. First-line therapy consists of either interferon-β, glatiramer acetate or teriflunomide. In general, agents used as escalation therapies (natalizumab, fingolimod and mitoxantrone) are more potent than the agents used for first-line therapy; however, these have potentially serious side effects and should be used with care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Cited by
Sphingolipid metabolism in cancer signalling and therapy
Ogretmen, B. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.96 · Cited by 1,207
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Immune responses to stroke: mechanisms, modulation, and therapeutic potential.
Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135530 · Cited by 853
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
How patients with multiple sclerosis acquire disability
Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain · doi:10.1093/brain/awac016 · Cited by 549
Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets
Tschoe, C., Bushnell, C. D., Duncan, P. W., Alexander-Miller, M. A., & Wolfe, S. Q. (2020) · Journal of Stroke · doi:10.5853/jos.2019.02236 · Cited by 490
(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00072 · Cited by 457
Quehenberger, O., & Dennis, E. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1104901 · Cited by 454
The Role of Astrocytes in Multiple Sclerosis
Ponath, G., Park, C., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00217 · Cited by 359
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Multiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330
Bankovich, A. J., Shiow, L. R., & Cyster, J. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.123299 · Cited by 307
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515616701 · Cited by 289
Impact of an immune modulator fingolimod on acute ischemic stroke
Fu, Y., Zhang, N., Ren, L., Yan, Y., Sun, N., Li, Y.-J., Han, W., Xue, R., Liu, Q., Hao, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416166111 · Cited by 288
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
Wang, Y., Spincemaille, P., Liu, Z., Dimov, A., Deh, K., Li, J., Zhang, Y., Yao, Y., Gillen, K. M., Wilman, A. H., et al. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25693 · Cited by 273
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
Lunde, H. M. B., Assmus, J., Myhr, K.-M., Bø, L., & Grytten, N. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315238 · Cited by 269
Sphingosine 1-phosphate and inflammation
Obinata, H., & Hla, T. (2019) · International Immunology · doi:10.1093/intimm/dxz037 · Cited by 268
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C., Lycke, J., Piehl, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912839117 · Cited by 194
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases
Chen, D., Zhang, T., & Lee, T. H. (2020) · Biomolecules · doi:10.3390/biom10081158 · Cited by 140
Chun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient
Yanagida, K., & Hla, T. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071635 · Cited by 109
Dusaban, S. S., Chun, J., Rosen, H., Purcell, N. H., & Brown, J. H. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0882-x · Cited by 106
Slowik, A., Schmidt, T., Beyer, C., Amor, S., Clarner, T., & Kipp, M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12938 · Cited by 94
Riganti, L., Antonucci, F., Gabrielli, M., Prada, I., Giussani, P., Viani, P., Valtorta, F., Menna, E., Matteoli, M., & Verderio, C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3588-15.2016 · Cited by 78
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Copland, D. A., Liu, J., Schewitz-Bowers, L. P., Brinkmann, V., Anderson, K., Nicholson, L. B., & Dick, A. D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.008 · Cited by 50
Diffusion MRI quantifies early axonal loss in the presence of nerve swelling
Lin, T.-H., Chiang, C.-W., Perez-Torres, C. J., Sun, P., Wallendorf, M., Schmidt, R. E., Cross, A. H., & Song, S.-K. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0852-3 · Cited by 42
Metadata
- Authors
- Kamm, C. P., Uitdehaag, B. M., & Polman, C. H.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 72
- Issue
- 3-4
- Pages
- 132-141
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W1986991730
- Cited by
- 1,010
- References
- 49
- FWCI
- 77.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.